On April 25, 2025 Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, reported the presentation of a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 25-30, 2025 in Chicago (Press release, Radiant Biotherapeutics, APR 25, 2025, View Source [SID1234652174]). The presentation describes the company’s Multabody platform, a novel approach to stimulating key targets in immunotherapy that have remained out of reach due to toxicity or lack of response.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation are below:

Presentation Title: Multabodies: A next-generation approach for cancer immunotherapy and 4-1BB agonist therapy
Abstract Number: 2889/28
Session Date and Time: April 28th 2:00-5:00 p.m.
Presenter: Joanne Hulme, Ph.D.